Format

Send to

Choose Destination
See comment in PubMed Commons below
Rev Med Suisse. 2011 Jan 19;7(278):103-5.

[Allergy-immunology. New therapies for acute attacks in hereditary angioedema].

[Article in French]

Author information

  • 1Service d'immunologie et d'allergie, CHUV, 1011 Lausanne. annette.leimgruber@chuv.ch

Abstract

Hereditary angioedema is a disease which develops as a result of a deficiency or dysfonction of C1-inhibitor, a key regulator of the complement, coagulation and contact cascades, resulting among others in excessive release of bradykinin. This disease mortality rate is high in absence of immediate and effective treatment, in particular in presence of acute attacks of the upper respiratory tract (laryngeal edema). Until now only administration of a purified C1-inhibitor extract was effective against these symptoms. This paper aims to synthesise essentials knowledge concerning news drugs, in particular icatibant, a selective bradykinin B2- receptor antagonist whose use should be widened to the treatment of angioedema with ACE-inhibitors intolerance.

PMID:
21400938
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk